LWMG
MBRX icon

Levy Wealth Management Group’s Moleculin Biotech MBRX Stock Holding History

Levy Wealth Management Group’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6
Closed -$11K – 68
2020
Q4 		$11K Buy
+6
New +$10.6K 0.01% 62

Other funds holding MBRX

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Levy Wealth Management Group's MBRX Position: Q1 2021 in Review

Levy Wealth Management Group sold out of Moleculin Biotech (MBRX) in Q1 2021, closing a stake of 6 shares — an estimated $11K sold.

Levy Wealth Management Group first reported a position in MBRX in Q4 2020 and held it in 1 quarter. The position peaked at $11K in Q4 2020. 27 funds tracked by Wall St. Rank hold MBRX as of Q1 2021.

  • Levy Wealth Management Group reported no remaining Moleculin Biotech position as of Q1 2021 after selling out during the quarter.
  • Levy Wealth Management Group sold 6 Moleculin Biotech shares in Q1 2021, an estimated $11K.
  • Levy Wealth Management Group first reported a position in Moleculin Biotech in Q4 2020 and held it in 1 quarter.
  • Levy Wealth Management Group's Moleculin Biotech position peaked at $11K in Q4 2020.
  • 27 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2021.

Based on Levy Wealth Management Group's 13F filing for Q1 2021, filed 10 May 2021.